Fresenius Medical Care (NYSE:FMS) Shares Gap Up to $19.54

Fresenius Medical Care AG (NYSE:FMS) gapped up before the market opened on Monday . The stock had previously closed at $19.54, but opened at $20.66. Fresenius Medical Care shares last traded at $20.68, with a volume of 272,203 shares traded.

Analysts Set New Price Targets

Several analysts recently issued reports on FMS shares. StockNews.com upgraded shares of Fresenius Medical Care from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 16th. Morgan Stanley lowered shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Fresenius Medical Care currently has an average rating of “Hold” and a consensus target price of $32.25.

Fresenius Medical Care Price Performance

The business’s 50 day moving average is $19.55 and its two-hundred day moving average is $19.45. The firm has a market cap of $12.61 billion, a P/E ratio of 23.35, a P/E/G ratio of 0.96 and a beta of 1.00. The company has a quick ratio of 1.07, a current ratio of 1.42 and a debt-to-equity ratio of 0.47.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. The business had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. As a group, analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Cuts Dividend

The firm also recently disclosed an annual dividend, which will be paid on Monday, June 3rd. Stockholders of record on Monday, May 20th will be issued a dividend of $0.437 per share. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend is Friday, May 17th. Fresenius Medical Care’s dividend payout ratio is currently 45.65%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in FMS. Pacer Advisors Inc. lifted its position in shares of Fresenius Medical Care by 14,252.1% during the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after purchasing an additional 484,998 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Fresenius Medical Care by 362.2% in the third quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares during the period. Moran Wealth Management LLC bought a new stake in shares of Fresenius Medical Care in the fourth quarter valued at approximately $3,247,000. Partnership Wealth Management LLC bought a new stake in shares of Fresenius Medical Care in the fourth quarter valued at approximately $2,340,000. Finally, O Shaughnessy Asset Management LLC raised its position in shares of Fresenius Medical Care by 259.5% in the third quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock valued at $1,995,000 after purchasing an additional 66,864 shares during the period. 8.25% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.